Results 131 to 140 of about 15,820 (232)

Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy. [PDF]

J Clin Med, 2020
Enevoldsen FC, Sahana J, Wehland M, Grimm D, Infanger M, Krüger M.   +5 more
europepmc   +1 more source

Heart–Lung Interactions in Pulmonary Hypertension due to Heart Failure With Preserved Ejection Fraction

Comprehensive Physiology, Volume 16, Issue 3, June 2026.
This review considers heart–lung interactions in pulmonary hypertension due to heart failure with preserved ejection fraction across scales, including organ, tissue, and cell scales. Key knowledge gaps in preclinical disease models, tools for clinical phenotyping, and underlying biological mechanisms are identified for future studies.
Pratima Prabala, Farhan Raza, Naomi C. Chesler   +2 more
wiley   +1 more source

Leptin in Obesity‐Related Heart Failure: Pathophysiological Mechanisms and Therapeutic Implications

Comprehensive Physiology, Volume 16, Issue 3, June 2026.
Obesity‐associated adipose tissue dysfunction leads to hyperleptinemia and altered leptin signaling. Through Ob‐Rb/LepR‐mediated pathways, leptin may contribute to neurohormonal activation, endothelial dysfunction, inflammation, oxidative stress, and myocardial remodeling.
Xuemin Li, Weiguo Wang, Yibo Zhang, Pengfei Ding, Xuewen Li   +4 more
wiley   +1 more source

Localization of the therapeutic targets for endothelin receptor antagonists and sodium-glucose co-transporter 2 inhibitors in the chronic liver disease, primary sclerosing cholangitis. [PDF]

Front Pharmacol
Kuc RE, Paterson AL, Williams TL, Gelson WTH, Greasley PJ, Ambery P, Maguire JJ, Davenport AP.   +7 more
europepmc   +1 more source

Oxygen Supplementation Improves Oxygen Uptake Kinetics and Exercise Performance in PAH and CTEPH Patients

Comprehensive Physiology, Volume 16, Issue 3, June 2026.
In patients with pulmonary vascular diseases (PAH and CTEPH), supplemental oxygen (FiO2 0.3), compared to room air (FiO2 0.21) improved peak exercise capacity (peak V̇O2), peak sustainable exercise (V̇O2 at GET), and V̇O2 kinetics and the onset of exercise.
Shir Kadosh, Yael Baidats, Andrew M. Jones, Daryl Wilkerson, Ariela Velner, Ronen Reuveny, Michael J. Segel   +6 more
wiley   +1 more source

Recent developments in the management of resistant hypertension: focus on endothelin receptor antagonists. [PDF]

Future Cardiol
Heidari Nejad S, Azzam O, Schlaich MP.
europepmc   +1 more source

Aspartame Increases the Risk of Pancreatic Ductal Adenocarcinoma

eFood, Volume 7, Issue 3, June 2026.
Aspartame (APM) is a widely used artificial sweetener associated with various health concerns, including potential links to diabetes, cardiovascular diseases, and an increased risk of cancer. A comprehensive approach incorporating data mining, machine learning, network toxicology, molecular docking, molecular dynamics simulations, and clinical sample ...
Jumin Xie, Wei Fang, Zean Song, Zhang Yu, Ying Zhu, Shaoping Liu   +5 more
wiley   +1 more source

Tadalafil plus endothelin receptor antagonists in connective tissue disease-associated pulmonary arterial hypertension: A multicenter study on exercise capacity and cardiac outcomes. [PDF]

Rheumatol Immunol Res
Wu Q, Ma H, Li D, Ye H, Zhou Z, Zhang N, Zhu Y, Liu T, Sun X, Zhang M, Wang Q.   +10 more
europepmc   +1 more source

Associations of C‐Reactive Protein–Triglyceride–Glucose Index With the Incidence and Progression of Cardiometabolic Multimorbidity in Middle‐Aged and Older Chinese Individuals: A Prospective Cohort Study From CHARLS

iLABMED, Volume 4, Issue 2, Page 65-77, June 2026.
This study investigated the association between C‐reactive protein‐triglyceride‐glucose index (CTI) and cardiometabolic multimorbidity (CMM) over a 9‐year follow‐up in a Chinese middle‐aged and older population. Higher CTI levels were significantly associated with an increased risk of CMM.
Zhengfeng Wu, Honghong Zhang, Yajun Zheng, Haijing Zhao, Jie Liu, Yuhan Ma, Yuqi Liu   +6 more
wiley   +1 more source

Endothelin Receptor Antagonists Plus Sodium-Glucose Cotransporter 2 Inhibitors: Poster Child for a New ERA of Combination Therapies? [PDF]

J Am Soc Nephrol
Limonte CP, de Boer IH.
europepmc   +1 more source